NO163986C - Fremgangsmaate for in vitro bedoemmelse av muligheten for cellekreft. - Google Patents

Fremgangsmaate for in vitro bedoemmelse av muligheten for cellekreft.

Info

Publication number
NO163986C
NO163986C NO834014A NO834014A NO163986C NO 163986 C NO163986 C NO 163986C NO 834014 A NO834014 A NO 834014A NO 834014 A NO834014 A NO 834014A NO 163986 C NO163986 C NO 163986C
Authority
NO
Norway
Prior art keywords
possibility
procedure
cell cancer
vitro assessing
assessing
Prior art date
Application number
NO834014A
Other languages
English (en)
Norwegian (no)
Other versions
NO163986B (no
NO834014L (no
Inventor
Martin J Cline
Dennis J Slamon
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of NO834014L publication Critical patent/NO834014L/no
Publication of NO163986B publication Critical patent/NO163986B/no
Publication of NO163986C publication Critical patent/NO163986C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO834014A 1982-11-04 1983-11-03 Fremgangsmaate for in vitro bedoemmelse av muligheten for cellekreft. NO163986C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43925282A 1982-11-04 1982-11-04
US49602783A 1983-05-19 1983-05-19

Publications (3)

Publication Number Publication Date
NO834014L NO834014L (no) 1984-05-07
NO163986B NO163986B (no) 1990-05-07
NO163986C true NO163986C (no) 1990-08-15

Family

ID=27031979

Family Applications (1)

Application Number Title Priority Date Filing Date
NO834014A NO163986C (no) 1982-11-04 1983-11-03 Fremgangsmaate for in vitro bedoemmelse av muligheten for cellekreft.

Country Status (16)

Country Link
EP (1) EP0108564B1 (fr)
JP (3) JPH0728759B2 (fr)
AU (1) AU559912B2 (fr)
BR (1) BR8306175A (fr)
CA (1) CA1252046A (fr)
DE (1) DE3376507D1 (fr)
DK (1) DK498083A (fr)
ES (2) ES8704005A1 (fr)
FI (1) FI79411B (fr)
GR (1) GR78948B (fr)
IE (1) IE56509B1 (fr)
IL (1) IL70067A (fr)
NO (1) NO163986C (fr)
NZ (1) NZ206096A (fr)
PH (1) PH20994A (fr)
PT (1) PT77605B (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713619B1 (en) 1980-08-29 2004-03-30 Massachusetts Institute Of Technology Oncogenes and methods for their detection
US4935341A (en) * 1986-06-04 1990-06-19 Whitehead Institute For Biomedical Research Detection of point mutations in neu genes
ZA84617B (en) * 1983-02-14 1984-09-26 Arup Sen Synthetic polypeptides from viryl oncogenes
US5733738A (en) * 1983-08-17 1998-03-31 Ligand Pharmaceuticals Polypeptide-induced monoclonal receptors to protein ligands
CA1219232A (fr) * 1983-08-17 1987-03-17 Richard A. Lerner Recepteurs monoclonaux induits par un polypeptide contre des ligands
US4762706A (en) * 1984-10-17 1988-08-09 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
EP0177814A3 (fr) * 1984-09-19 1987-12-02 Cetus Corporation Anticorps contre les peptides et leurs utilisation dans la détection des produits d'oncogènes
US4798787A (en) * 1984-09-19 1989-01-17 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
IL76997A0 (en) * 1984-11-14 1986-04-29 Oncogene Science Inc Probes and methods useful for detecting chromosomal translocation
US5084380A (en) * 1985-01-29 1992-01-28 Applied Biotechnology Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
CA1296660C (fr) * 1985-01-29 1992-03-03 Walter P. Carney Anticorps monoclonal dirige contre un dodecapeptide relie a un oncogene p21 ras
US5081230A (en) * 1987-07-08 1992-01-14 E. I. Dupont Denemours And Company Monoclonal antibodies reactive with normal and oncogenic forms of the ras p21 protein
US4898932A (en) * 1985-01-29 1990-02-06 E. I. Du Pont De Nemours And Company Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
US5443956A (en) * 1985-01-29 1995-08-22 Oncogene Science, Inc. Detection, quantitation and classification of RAS proteins in body fluids and tissues
US6200764B1 (en) 1985-01-29 2001-03-13 Bayer Corporation Detection, quantitation and classification of ras proteins in body fluids and tissues
US5028527A (en) * 1988-02-22 1991-07-02 Applied Bio Technology Monoclonal antibodies against activated ras proteins with amino acid mutations at position 13 of the protein
WO1986005816A1 (fr) * 1985-04-04 1986-10-09 Georgetown University Sequences adn et peptides specifiques au virus du papillome
EP0203587A3 (fr) * 1985-05-30 1989-08-09 F. Hoffmann-La Roche Ag Peptides ras oncogènes et anticorps
EP0206065A3 (fr) * 1985-06-27 1989-04-19 James R. Feramisco Méthode de détection de protéines oncogéniques et proto-oncogéniques dans les fluides biologiques extracellulaires
US6083709A (en) * 1985-08-21 2000-07-04 Osi Pharmaceuticals, Inc. Immunoassay for detection of mutant P53 polypeptide in serum
AU615876B2 (en) * 1985-08-21 1991-10-17 Oncogene Science, Inc. Immunoassay for the detection of Oncogene encoded products
FR2594833B1 (fr) * 1986-02-26 1989-04-28 Centre Nat Rech Scient Proteines homologues de celles codees par des oncogenes humains, procede d'obtention de ces proteines et leurs applications immunologiques, physiopathologiques et therapeutiques
FI76119C (fi) * 1986-02-27 1988-09-09 Orion Yhtymae Oy Kvantitativ bestaemning av nukleinsyramolekyler och reagensfoerpackning som anvaends vid foerfarandet.
EP0246709A1 (fr) * 1986-05-20 1987-11-25 Stichting Katholieke Universiteit ADN recombinant et ADN complémentaire, ARN messager, protéine, anticorps et méthode de détection de cellules tumorales
US5320941A (en) * 1986-06-06 1994-06-14 Dallan Young DNA sequence encoding mas onhcogene, polypeptides encoded therefrom and diagnostic and other methods based therefrom
JPS6374492A (ja) * 1986-09-18 1988-04-04 Hiroshi Shiyuku モノクロ−ナル抗体
US5085983A (en) * 1988-08-19 1992-02-04 City Of Hope Detection of human tumor progression and drug resistance
EP0290144A1 (fr) * 1987-05-05 1988-11-09 City of Hope Méthode de détection de résistance naissante à des agents thérapeutiques chez des malades cancéreux
EP0304845A3 (fr) * 1987-08-28 1991-03-06 Profile Diagnostic Sciences Inc. Procédé et composition pour déterminer l'expression des gènes
EP0412116B1 (fr) * 1988-04-18 1995-11-29 Oncogene Science, Inc. Detection d'expression de genes neu et produits
EP0428518A4 (en) * 1988-04-22 1992-02-19 E.I. Du Pont De Nemours And Company Monoclonal antibodies specific for the harvey, kirsten and n ras proteins and their use as diagnostic reagents
US5760203A (en) * 1988-08-10 1998-06-02 Chiron Corporation Gap gene sequences
US5763573A (en) * 1988-08-10 1998-06-09 Chiron Corporation GTPase activating protein fragments
ATE160877T1 (de) * 1988-08-12 1997-12-15 Ligand Pharm Inc Polypeptid-induzierte monoklonale rezeptoren gegen proteinliganden
FR2637600B1 (fr) * 1988-10-11 1992-03-06 Pasteur Institut Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
US7442761B2 (en) * 2003-06-06 2008-10-28 Samuel Bogoch Replikin peptides and uses thereof
US7774144B2 (en) 2001-10-26 2010-08-10 Samuel Bogoch System and method for identifying complex patterns of amino acids
US7452963B2 (en) 2001-03-27 2008-11-18 Samuel Bogoch Replikin peptides and antibodies therefore
NZ592340A (en) 2001-03-27 2012-12-21 Elenore S Bogoch A method for making a virus vaccine compising Replikin peptides
US7189800B2 (en) 2001-03-27 2007-03-13 Samuel Bogoch Replikin peptides in rapid replication of glioma cells and in influenza epidemics
US7420028B2 (en) 2001-03-27 2008-09-02 Samuel Bogoch Replikins and methods of identifying replikin-containing sequences
US7894999B2 (en) 2001-03-27 2011-02-22 Samuel Bogoch Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
EP2261368A1 (fr) 2002-03-13 2010-12-15 Genomic Health, Inc. Profilage de l'expression génétique dans des tissus de tumeurs prélevées par biopsie
AU2003295598B2 (en) 2002-11-15 2009-12-24 Genomic Health, Inc. Gene expression profiling of EGFR positive cancer
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA2516553C (fr) 2003-02-20 2013-04-16 Genomic Health, Inc. Utilisation d'arn intronique pour mesurer l'expression genique
US8494781B2 (en) 2003-06-06 2013-07-23 Samuel Bogoch Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
ES2787475T3 (es) 2003-06-24 2020-10-16 Genomic Health Inc Predicción de probabilidad de recurrencia del cáncer
CA2531967C (fr) 2003-07-10 2013-07-16 Genomic Health, Inc. Algorithme de profile d'expression et test du pronostic du cancer
ES2360113T3 (es) 2003-12-23 2011-06-01 Genomic Health, Inc. Amplificación universal de rna fragmentado.
ITPD20040065A1 (it) * 2004-03-15 2004-06-15 Univ Padova Peptidi della vitronectina e loro impiego terapeutico nella adesione degli osteoblasti
JP5813908B2 (ja) 2004-04-09 2015-11-17 ジェノミック ヘルス， インコーポレイテッド 化学療法剤に対する応答を予測するための遺伝子発現マーカー
US9254315B2 (en) 2004-04-28 2016-02-09 Samuel Bogoch Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
CA2585571C (fr) 2004-11-05 2020-01-21 Genomic Health, Inc. Prediction de reaction a la chimiotherapie au moyen de marqueurs d'expression genique
CA2585561C (fr) 2004-11-05 2018-07-17 Genomic Health, Inc. Resultat de groupe esr1, pgr, bcl2 et scube2 comme indicateurs de pronostic de cancer du sein et de prediction de la reponse au traitement
US8050871B2 (en) 2006-10-24 2011-11-01 Samuel Bogoch Method of predicting influenza outbreaks by correlating an increase in replikin count in shrimp white spot syndrome virus and/or taura syndrome virus
AU2008266702A1 (en) 2007-05-30 2008-12-24 Elenore S. Bogoch Synthetic replikin peptides against pathogenic infection of invertebrates in aquaculture
US9233148B2 (en) 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
US9320784B2 (en) 2009-08-07 2016-04-26 Samuel Bogoch Peptides shared among lethal cancers and therapeutic compositions comprising said peptides
US9328142B2 (en) 2011-05-25 2016-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lipopeptide inhibitors of RAS oncoproteins
DK3511443T3 (da) 2016-09-09 2021-08-02 De Nora Permelec Ltd Fremgangsmåde til fremstilling af anode til alkalisk vandelektrolyse og anode til alkalisk vandelektrolyse

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1598686A (en) * 1977-04-29 1981-09-23 Dia Prosim Enzymes immobilised on a resin via chelation with a metal
IT1207172B (it) * 1979-02-15 1989-05-17 Anic Spa Processo per la preparazione dicorpi microporosi inglobanti uno o piu' agenti attivi.
ZA811368B (en) * 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
ES8302778A1 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
GB2108510B (en) * 1981-10-03 1984-12-12 Ciba Geigy Ag Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof

Also Published As

Publication number Publication date
NZ206096A (en) 1986-09-10
IL70067A (en) 1989-08-15
DE3376507D1 (en) 1988-06-09
JPH07215995A (ja) 1995-08-15
EP0108564B1 (fr) 1988-05-04
JPS59113898A (ja) 1984-06-30
PH20994A (en) 1987-06-18
NO163986B (no) 1990-05-07
IL70067A0 (en) 1984-01-31
IE832493L (en) 1984-05-04
CA1252046A (fr) 1989-04-04
DK498083A (da) 1984-05-05
JPH05328965A (ja) 1993-12-14
FI833952A (fi) 1984-05-05
NO834014L (no) 1984-05-07
ES8600215A1 (es) 1985-10-01
JPH0728759B2 (ja) 1995-04-05
ES8704005A1 (es) 1987-03-01
DK498083D0 (da) 1983-10-31
EP0108564A1 (fr) 1984-05-16
PT77605A (en) 1983-12-01
AU2065083A (en) 1984-05-10
FI79411B (fi) 1989-08-31
ES526991A0 (es) 1987-03-01
PT77605B (en) 1986-05-05
JPH0759188B2 (ja) 1995-06-28
JP2716670B2 (ja) 1998-02-18
FI833952A0 (fi) 1983-10-28
BR8306175A (pt) 1984-06-12
GR78948B (fr) 1984-10-02
AU559912B2 (en) 1987-03-26
IE56509B1 (en) 1991-08-28
ES533105A0 (es) 1985-10-01

Similar Documents

Publication Publication Date Title
NO163986C (no) Fremgangsmaate for in vitro bedoemmelse av muligheten for cellekreft.
FI834222A (fi) Elektrolytiskt foerfarande och elektrolytisk cell foer framstaellning av organiska foereningar.
FR2534829B1 (fr) Broyeur en cone
DK180683A (da) Reformingkatalysator
ATE29595T1 (de) Pruefverfahren.
DK188583A (da) Skaelmiddel
NO834867L (no) Reaksjonssintret cermet
DE3370594D1 (de) Diffusion cell
ES522754A0 (es) Procedimiento de obtener alcaloides del tipo de la berberina y similares.
FI843131A (fi) Elektrolytisk cell foer tillvaratagande av metaller fraon metallbaerande material.
FI831772L (fi) I under tryck staoende behaollare anvaendbar foerdelningsventil
FI781164A (fi) Anordning foer upphaengning av koepkassar i en knippa
NO165079C (no) Elektrolysecelle for fremstilling av magnesium.
NO160335C (no) Fremgangsmaate for fremstilling av roerkokiller.
FI834204A (fi) Anordning foer haollning av sliden i blixtlaos.
FI834074A0 (fi) Foerbaettrad reglering av vingens stigningsvinkel foer stora vindturbiner
ES522662A0 (es) Procedimiento para preparar piridil y quinolil-imidazolinonas.
NO152387C (no) Undervisningsbord
FR2536569B1 (fr) Tourne-disque
DK514683D0 (da) Amfibiecampingvogn
AT386842B (de) Brikettierverfahren
NO155379C (no) Konknuser
AT377201B (de) Musermuehle
FI823177A0 (fi) Foerfarande foer foerbaettring av avdunstbarhet av avfallsvaetska uppstaodd under cellulosaframstaellningsprocess
SE8107877L (sv) Anodaggregat for litium-halogenceller

Legal Events

Date Code Title Description
MK1K Patent expired

Free format text: EXPIRED IN NOVEMBER 2003

MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN NOVEMBER 2003